ALSUntangled #67: rituximab.
Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L Feldman, Jonathan Glass, Jill Goslinga, Terry Heiman-Patterson, Sartaj Jhooty, Rachel Lichtenstein, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Kristiana Salmon, Paul Wicks, Richard Bedlack
Amyotrophic lateral sclerosis & frontotemporal degeneration 2023 AugALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.
Citation
Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L Feldman, Jonathan Glass, Jill Goslinga, Terry Heiman-Patterson, Sartaj Jhooty, Rachel Lichtenstein, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Kristiana Salmon, Paul Wicks, Richard Bedlack. ALSUntangled #67: rituximab. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2023 Aug;24(5-6):544-547
Mesh Tags
Substances
PMID: 36106861
View Full Text
